Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Scancell Holdings ( (GB:SCLP) ) is now available.
Scancell Holdings plc announced that it will release its interim results for the six months ended October 31, 2024, on January 30, 2025. The announcement will be accompanied by a virtual analyst briefing and a live webcast with a Q&A session. This could potentially impact stakeholders by providing updated insights into the company’s progress and future outlook in the biopharmaceutical industry.
More about Scancell Holdings
Scancell Holdings plc is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. It leverages proprietary research in the human adaptive immune system to create novel medicines addressing significant unmet cancer treatment needs. The company utilizes four technology platforms: Moditope® and ImmunoBody® for vaccines, and GlyMab® and AvidiMab® for antibodies, aiming to target protein and lipid modifications in cancerous or infected cells.
YTD Price Performance: -10.23%
Average Trading Volume: 1,166,199
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £100M
Find detailed analytics on SCLP stock on TipRanks’ Stock Analysis page.
